Lyudmila V. Shogenova
Lyudmila V. Shogenova has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander G. Chuchalin
Pirogov Russian National Research Medical University
7 shared publications - Anna M. Ryabokon
Russian Academy of Sciences
4 shared publications - Sergey D. Varfolomeev
Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia
4 shared publications - Irina I. Utkina
N.V. Sklifosovsky Research Institute for Emergency Medicine
3 shared publications - Pavel V. Gavrilov
N.V. Sklifosovsky Research Institute for Emergency Medicine
3 shared publications - Sergey Vladimirovich Zhuravel
N.V. Sklifosovsky Research Institute for Emergency Medicine; Pirogov Russian National Research Medical University; A.I. Yevdokimov Moscow State University of Medicine and Dentistry
3 shared publications
Latest Publications
- Open Access
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 511-521
Efficacy and safety of inhalation therapy with thermal heliumoxygen mixture in patients with exacerbation of chronic obstructive pulmonary disease complicated by hypoxemic and hypercapnic respiratory failure and secondary pulmonary arterial hypertension
The most formidable complication and the most common reason for hospitalization of patients with chronic obstructive pulmonary disease (COPD) is respiratory failure (RF), in the treatment of which respiratory support is actively used. However, respiratory support is ineffective in 30% of patients with severe exacerbation of COPD combined with hypoxemia and hypercapnia, which necessitates the search for new methods to correct RF.The aim of the study was to determine the efficacy and safety of thermal heliox (t-He/O2) in the treatment of exacerbation of COPD complicated by hypoxemic and hypercapnic RF and secondary pulmonary hypertension (PH) (group III according to the classification of the World Health Organization). Methods. The comparative controlled parallel prospective study included patients (n = 80: 49 men, 31 women) with exacerbation of COPD of categories C and D according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2021 – 2023), complicated by hypoxemic, hypercapnic respiratory failure and PH. The patients (n = 80) were similar in demographic, clinical and functional parameters and received noninvasive ventilation (NIV) with biphasic positive airway pressure (BiPAP S/T) and oxygen (O2) to maintain hemoglobin oxygen saturation (SpO2) at 95–97% in addition to standard drug therapy. The patients were divided into 2 groups: group 1 (n = 40: 25 men, 15 women) received t-He/O2 inhalations twice a day for 30 min (a total of 60 min per day); group 2 (n = 40: 24 men, 16 women) did not receive t-He/O2 inhalations. The dynamics of the clinical condition of patients, gas exchange in the lungs, acid-base balance, left-to-right shunt fraction, oxygen delivery, integral hemodynamic indices, external respiratory function (ERF), and exercise tolerance (ET) were assessed.Results. When using t-He/O2 in patients with COPD with hypercapnic, hypoxemic DN and PH against the background of standard therapy, a positive effect was demonstrated not only on the clinical condition of patients, but also on central hemodynamics, as well as a significant improvement in ERF, ET, arterial blood gas composition, acid-base balance and intrapulmonary shunt fraction, partial pressure of oxygen and carbon dioxide in arterial blood, hemoglobin oxygen saturation, as well as the concentration of bicarbonate ions and lactate in arterial blood compared with such indices in patients in the control group.Conclusion. It has been established that t-He/O2 inhalations in parallel with NIVL are safe and effective compared to oxygen therapy, while improving cardiac function and the clinical condition of patients, reducing the severity of dyspnea and signs of hypoxemia and hypercapnia, increasing the ET due to increased oxygen delivery to tissues, normalizing gas exchange in the lungs, reducing the shunt fraction, and restoring the level of bicarbonates and lactate in the blood.
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 511-521
Open AccessEfficacy and safety of inhalation therapy with thermal heliumoxygen mixture in patients with exacerbation of chronic obstructive pulmonary disease complicated by hypoxemic and hypercapnic respiratory failure and secondary pulmonary arterial hypertension
The most formidable complication and the most common reason for hospitalization of patients with chronic obstructive pulmonary disease (COPD) is respiratory failure (RF), in the treatment of which respiratory support is actively used. However, respiratory support is ineffective in 30% of patients with severe exacerbation of COPD combined with hypoxemia and hypercapnia, which necessitates the search for new methods to correct RF.The aim of the study was to determine the efficacy and safety of thermal heliox (t-He/O2) in the treatment of exacerbation of COPD complicated by hypoxemic and hypercapnic RF and secondary pulmonary hypertension (PH) (group III according to the classification of the World Health Organization). Methods. The comparative controlled parallel prospective study included patients (n = 80: 49 men, 31 women) with exacerbation of COPD of categories C and D according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2021 – 2023), complicated by hypoxemic, hypercapnic respiratory failure and PH. The patients (n = 80) were similar in demographic, clinical and functional parameters and received noninvasive ventilation (NIV) with biphasic positive airway pressure (BiPAP S/T) and oxygen (O2) to maintain hemoglobin oxygen saturation (SpO2) at 95–97% in addition to standard drug therapy. The patients were divided into 2 groups: group 1 (n = 40: 25 men, 15 women) received t-He/O2 inhalations twice a day for 30 min (a total of 60 min per day); group 2 (n = 40: 24 men, 16 women) did not receive t-He/O2 inhalations. The dynamics of the clinical condition of patients, gas exchange in the lungs, acid-base balance, left-to-right shunt fraction, oxygen delivery, integral hemodynamic indices, external respiratory function (ERF), and exercise tolerance (ET) were assessed.Results. When using t-He/O2 in patients with COPD with hypercapnic, hypoxemic DN and PH against the background of standard therapy, a positive effect was demonstrated not only on the clinical condition of patients, but also on central hemodynamics, as well as a significant improvement in ERF, ET, arterial blood gas composition, acid-base balance and intrapulmonary shunt fraction, partial pressure of oxygen and carbon dioxide in arterial blood, hemoglobin oxygen saturation, as well as the concentration of bicarbonate ions and lactate in arterial blood compared with such indices in patients in the control group.Conclusion. It has been established that t-He/O2 inhalations in parallel with NIVL are safe and effective compared to oxygen therapy, while improving cardiac function and the clinical condition of patients, reducing the severity of dyspnea and signs of hypoxemia and hypercapnia, increasing the ET due to increased oxygen delivery to tissues, normalizing gas exchange in the lungs, reducing the shunt fraction, and restoring the level of bicarbonates and lactate in the blood.
- Open Access
- 25 June 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (3) , 359-369
Efficacy and safety of the combined use of medical gases in patients with exacerbation of chronic obstructive pulmonary disease and secondary pulmonary arterial hypertension in the post-COVID period
The interest in medical gases for the correction of respiratory failure (RF) has been growing over recent years. However, there are virtually no scientific studies of combination therapy for exacerbation of chronic obstructive pulmonary disease (COPD), which is a combination of non-invasive ventilation (NIV) with thermal heliox (t-He/O2), nitric oxide (NO2) and molecular hydrogen (H2), in the Russian Federation and in the world.The aim of the study was to investigate the efficacy and safety of the combined use of t-He/O2, NO and H2 in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic RF and secondary pulmonary hypertension (PH) in the post-COVID period.Methods. The randomized, comparative, controlled, parallel-group, prospective study included 100 patients (52 men, 48 women) with exacerbation of COPD categories C and D according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2021 – 2023), with hypoxemic, hypercapnic respiratory failure and PH, who had COVID-19 (COronaVIrus Disease 2019) complicated by pneumonia caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) before the hospitalization. Patients with similar demographic, clinical, and functional parameters, who received, along with standard drug therapy, NIV in the spontaneous-forced biphasic positive airway pressure (BiPAP S/T) mode and oxygen (O2) to maintain blood hemoglobin oxygen saturation (SpO2) in the range of 95–97% according to GOLD (2021 – 2023), were divided into 5 groups: patients of the 1st (main) group (n = 22: 12 men, 10 women) received t-He/O2, NO, and H2 sequentially; the 2nd group (n = 20: 10 men, 10 women) – t-He/O2 and NO; the 3rd group (n = 20: 11 men, 9 women) – t-He/O2 and H2; the 4th group (n = 18: 10 men, 8 women) – NO and H2; the 5th group (control) (n = 20: 9 men, 11 women) – only standard drug therapy, NIV and O2. Changes in the clinical condition of the patients, gas exchange in the lungs, acid-base balance, left-to-right shunt fraction, hemodynamic parameters, and exercise tolerance (ET) were assessed.Results. Not only clinical condition of the patients, but also the arterial blood gas composition, acid-base balance and intrapulmonary blood shunt fraction, hemodynamics and ET were improved in the main group compared to those in patients who received inhalation therapy with medical gases separately and the control group.Conclusion. The combination of t-He/O2, NO and H2 combined with pathogenetic therapy and NIV in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic DN and secondary PH in the post-COVID period is safe and more effective compared to administering each medical gas separately. The clinical condition of patients improves, signs of hypoxemia and hypercapnia, vascular endothelial dysfunction, and metabolic disorders are reduced with the combined therapy. An increase in ET was also noted due to the normalization of gas exchange in the lungs, increased oxygen delivery to tissues, a decrease in the shunt fraction, and restoration of metabolism.
- 25 June 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (3) , 359-369
Open AccessEfficacy and safety of the combined use of medical gases in patients with exacerbation of chronic obstructive pulmonary disease and secondary pulmonary arterial hypertension in the post-COVID period
The interest in medical gases for the correction of respiratory failure (RF) has been growing over recent years. However, there are virtually no scientific studies of combination therapy for exacerbation of chronic obstructive pulmonary disease (COPD), which is a combination of non-invasive ventilation (NIV) with thermal heliox (t-He/O2), nitric oxide (NO2) and molecular hydrogen (H2), in the Russian Federation and in the world.The aim of the study was to investigate the efficacy and safety of the combined use of t-He/O2, NO and H2 in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic RF and secondary pulmonary hypertension (PH) in the post-COVID period.Methods. The randomized, comparative, controlled, parallel-group, prospective study included 100 patients (52 men, 48 women) with exacerbation of COPD categories C and D according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2021 – 2023), with hypoxemic, hypercapnic respiratory failure and PH, who had COVID-19 (COronaVIrus Disease 2019) complicated by pneumonia caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) before the hospitalization. Patients with similar demographic, clinical, and functional parameters, who received, along with standard drug therapy, NIV in the spontaneous-forced biphasic positive airway pressure (BiPAP S/T) mode and oxygen (O2) to maintain blood hemoglobin oxygen saturation (SpO2) in the range of 95–97% according to GOLD (2021 – 2023), were divided into 5 groups: patients of the 1st (main) group (n = 22: 12 men, 10 women) received t-He/O2, NO, and H2 sequentially; the 2nd group (n = 20: 10 men, 10 women) – t-He/O2 and NO; the 3rd group (n = 20: 11 men, 9 women) – t-He/O2 and H2; the 4th group (n = 18: 10 men, 8 women) – NO and H2; the 5th group (control) (n = 20: 9 men, 11 women) – only standard drug therapy, NIV and O2. Changes in the clinical condition of the patients, gas exchange in the lungs, acid-base balance, left-to-right shunt fraction, hemodynamic parameters, and exercise tolerance (ET) were assessed.Results. Not only clinical condition of the patients, but also the arterial blood gas composition, acid-base balance and intrapulmonary blood shunt fraction, hemodynamics and ET were improved in the main group compared to those in patients who received inhalation therapy with medical gases separately and the control group.Conclusion. The combination of t-He/O2, NO and H2 combined with pathogenetic therapy and NIV in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic DN and secondary PH in the post-COVID period is safe and more effective compared to administering each medical gas separately. The clinical condition of patients improves, signs of hypoxemia and hypercapnia, vascular endothelial dysfunction, and metabolic disorders are reduced with the combined therapy. An increase in ET was also noted due to the normalization of gas exchange in the lungs, increased oxygen delivery to tissues, a decrease in the shunt fraction, and restoration of metabolism.
- Open Access
- 21 June 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (3) , 159-164
Efficacy and safety of combined therapy with thermal heliox and nitric oxide during noninvasive ventilation in patients with acute chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary hypertension
Aim. To study the efficacy and safety of combination therapy of thermal heliox (t-He/O2) and nitric oxide (NO) in patients with acute chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary arterial hypertension (PAH) [group III PAH according to the classification of the World Health Organization]. Materials and methods. The study included 180 patients (GOLD C/D) divided into four groups: Group 1 (t-He/O₂ + non-invasive ventilation – NIV), Group 2 (NO + NIV), Group 3 (t-He/O₂ + NO + NIV), and Group 4 (control, receiving NIV alone). Clinical, gas exchange, and hemodynamic parameters were evaluated. Results. Combined therapy (Group 3) demonstrated the highest efficacy: respiratory rate decreased to 16.2±0.9 breaths/min, partial pressure of arterial carbon dioxide (PaCO₂) reduced to 41.7±2.9 mm Hg, partial pressure of arterial oxygen (PaO₂) increased to 80.8±8.9 mm Hg, and exercise tolerance improved (six-minute walk test [6MWT]: +805±156%). Minimal improvements were observed in the control group. Conclusion. The combination of t-He/O₂ and NO with NIV is safe and more effective than monotherapy or NIV alone.
- 21 June 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (3) , 159-164
Open AccessEfficacy and safety of combined therapy with thermal heliox and nitric oxide during noninvasive ventilation in patients with acute chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary hypertension
Aim. To study the efficacy and safety of combination therapy of thermal heliox (t-He/O2) and nitric oxide (NO) in patients with acute chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary arterial hypertension (PAH) [group III PAH according to the classification of the World Health Organization]. Materials and methods. The study included 180 patients (GOLD C/D) divided into four groups: Group 1 (t-He/O₂ + non-invasive ventilation – NIV), Group 2 (NO + NIV), Group 3 (t-He/O₂ + NO + NIV), and Group 4 (control, receiving NIV alone). Clinical, gas exchange, and hemodynamic parameters were evaluated. Results. Combined therapy (Group 3) demonstrated the highest efficacy: respiratory rate decreased to 16.2±0.9 breaths/min, partial pressure of arterial carbon dioxide (PaCO₂) reduced to 41.7±2.9 mm Hg, partial pressure of arterial oxygen (PaO₂) increased to 80.8±8.9 mm Hg, and exercise tolerance improved (six-minute walk test [6MWT]: +805±156%). Minimal improvements were observed in the control group. Conclusion. The combination of t-He/O₂ and NO with NIV is safe and more effective than monotherapy or NIV alone.
- Open Access
- 15 April 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (3) , 242-249
Efficiency and safety of the integrated use of medical gases thermal heliox, nitric oxide and molecular hydrogen in patients with exacerbation of chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary arterial hypertension in the post-COVID period
Aim. To study the efficacy and safety of the combined use of thermal heliox (t-He/O2), nitric oxide (NO) and molecular hydrogen (H2) in patients with exacerbation of chronic obstructive pulmonary disease (COPD) complicated by hypoxemic, hypercapnic respiratory failure (RF) and secondary pulmonary arterial hypertension (PAH) in the post-COVID period. Materials and methods. The randomized, comparative, controlled, parallel study included patients (n=100, 52 men and 48 women) with exacerbation of COPD levels of evidence C and D (GOLD 2021–2023) with hypoxemic, hypercapnic respiratory failure and secondary PAH, who had pneumonia caused by SARS-CoV-2 before hospitalization. Patients with similar demographic, clinical, and functional parameters, who received non-invasive ventilation (NIV) and oxygen (O2) along with standard drug therapy, were divided into 5 groups: Group 1 (main): (n=22: 12 men, 10 women, who received t-He/O2, NO, and H2 sequentially); Group 2 (n=20: 10 men, 10 women, who received t-He/O2 and NO); Group 3 (n=20: 11 men, 9 women, who received t-He/O2 and H2); Group 4 (n=18: 10 men, 8 women, who received NO and H2); Group 5 (control) (n=20: 9 men, 11 women). The dynamics of the clinical condition of patients, gas exchange in the lungs, acid-base balance, left-to-right discharge fraction, hemodynamic parameters, and exercise tolerance were assessed. Results. A positive effect of the complex use of medical gases on the clinical condition of patients, gas exchange parameters in the lungs, metabolism, hemodynamic parameters and exercise tolerance was found in comparison with these parameters in patients who received medical gases separately and with the control group. Conclusion. The combination of t-He/O2, NO and H2 with simultaneous pathogenetic therapy and NIV in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic RF and secondary PAH in the post-COVID period is safe and more effective compared to groups receiving each medical gas separately. Complex therapy improves the clinical condition of patients, reduces signs of hypoxemia and hypercapnia, vascular endothelial dysfunction, metabolic disorders and increases tolerance to physical activity by normalizing gas exchange in the lungs, increasing oxygen delivery to tissues, reducing the shunt fraction, and restoring metabolism.
- 15 April 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (3) , 242-249
Open AccessEfficiency and safety of the integrated use of medical gases thermal heliox, nitric oxide and molecular hydrogen in patients with exacerbation of chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary arterial hypertension in the post-COVID period
Aim. To study the efficacy and safety of the combined use of thermal heliox (t-He/O2), nitric oxide (NO) and molecular hydrogen (H2) in patients with exacerbation of chronic obstructive pulmonary disease (COPD) complicated by hypoxemic, hypercapnic respiratory failure (RF) and secondary pulmonary arterial hypertension (PAH) in the post-COVID period. Materials and methods. The randomized, comparative, controlled, parallel study included patients (n=100, 52 men and 48 women) with exacerbation of COPD levels of evidence C and D (GOLD 2021–2023) with hypoxemic, hypercapnic respiratory failure and secondary PAH, who had pneumonia caused by SARS-CoV-2 before hospitalization. Patients with similar demographic, clinical, and functional parameters, who received non-invasive ventilation (NIV) and oxygen (O2) along with standard drug therapy, were divided into 5 groups: Group 1 (main): (n=22: 12 men, 10 women, who received t-He/O2, NO, and H2 sequentially); Group 2 (n=20: 10 men, 10 women, who received t-He/O2 and NO); Group 3 (n=20: 11 men, 9 women, who received t-He/O2 and H2); Group 4 (n=18: 10 men, 8 women, who received NO and H2); Group 5 (control) (n=20: 9 men, 11 women). The dynamics of the clinical condition of patients, gas exchange in the lungs, acid-base balance, left-to-right discharge fraction, hemodynamic parameters, and exercise tolerance were assessed. Results. A positive effect of the complex use of medical gases on the clinical condition of patients, gas exchange parameters in the lungs, metabolism, hemodynamic parameters and exercise tolerance was found in comparison with these parameters in patients who received medical gases separately and with the control group. Conclusion. The combination of t-He/O2, NO and H2 with simultaneous pathogenetic therapy and NIV in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic RF and secondary PAH in the post-COVID period is safe and more effective compared to groups receiving each medical gas separately. Complex therapy improves the clinical condition of patients, reduces signs of hypoxemia and hypercapnia, vascular endothelial dysfunction, metabolic disorders and increases tolerance to physical activity by normalizing gas exchange in the lungs, increasing oxygen delivery to tissues, reducing the shunt fraction, and restoring metabolism.
- Open Access
- 12 December 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (1) , 118-124
Respiratory salon as a new organizational model in healthcare
Fundamentally new approaches to the therapy of respiratory insufficiency (RI) have been developed based on the modern understanding of its pathogenesis. A new structure “Respiratory Salon” has been designed to solve the most important clinical and methodological problems facing public health in the field related to the use of medical gases in respiratory diseases. The aim of the work was to create “Respiratory Salon” for the complex treatment of respiratory insufficiency by medical gases. Conclusion. Fundamentally new approaches to the therapy of RI have been developed based on the modern understanding of its pathogenesis and a new structure named “Respiratory salon” has been created. The positive experience of the organization of “Respiratory Salon” for correction of respiratory insufficiency by medical gases in inpatient, outpatient and, therapeutic resort conditions is presented.
- 12 December 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (1) , 118-124
Open AccessRespiratory salon as a new organizational model in healthcare
Fundamentally new approaches to the therapy of respiratory insufficiency (RI) have been developed based on the modern understanding of its pathogenesis. A new structure “Respiratory Salon” has been designed to solve the most important clinical and methodological problems facing public health in the field related to the use of medical gases in respiratory diseases. The aim of the work was to create “Respiratory Salon” for the complex treatment of respiratory insufficiency by medical gases. Conclusion. Fundamentally new approaches to the therapy of RI have been developed based on the modern understanding of its pathogenesis and a new structure named “Respiratory salon” has been created. The positive experience of the organization of “Respiratory Salon” for correction of respiratory insufficiency by medical gases in inpatient, outpatient and, therapeutic resort conditions is presented.
- Open Access
- 11 October 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (5) , 655-667
Efficacy and safety of inhaled molecular hydrogen therapy in patients with respiratory failure due to chronic obstructive pulmonary disease exacerbation in post-COVID period
Molecular hydrogen (H2) is a powerful antioxidant and anti-apoptotic agent. H2 has been studied in a number of clinical studies in the recent years.The aim of this research was to investigate the efficacy and safety of H2 inhalation therapy in patients with hypoxemic and hypercapnic respiratory failure (RF) against exacerbation of chronic obstructive pulmonary disease (COPD) in the post-COVID (Corona Virus Disease 2019) period.Methods. The randomized prospective parallel comparative study included patients (n = 60: 40 men aged 71.2 ± 1.8 years, 20 women aged 70.9 ± 2.8 years) with a post-COVID-19 exacerbation of COPD complicated by hypoxemic/hypercapnic RF. The patients were divided into 2 groups: group 1 (main) (n = 30: 18 men, 12 women), group 2 (control) (n = 30: 18 men, 12 women). To maintain arterial blood saturation ≥ 90 %, patients in both groups received respiratory support (non-invasive ventilation) using the Prisma 25ST device (Lowenstein Medical, Germany) in the BiPAP S/T mode (BiLevel Positive Airway Pressure Spontaneous/Time spontaneous/forced mode 20–24/4–6 cm H2O and O2, respectively; the fractional oxygen concentration in the inhaled gas mixture was ≥ 24%). In addition to standard treatment, patients in the main group received additional H2 therapy (Suisonia device, Japan) through a nasal cannula for 90 minutes daily for 14 days.Results. In patients of the main group, a decrease in the stiffness index was detected from 14.6 ± 1.2 to 6.2 ± 0.6 m/s, and the arterial blood lactate level – from 2.84 ± 0.1 to 0.02 ± 0.1 mmol/l (p < 0.001), the calculated shunt fraction Qs/Qt (venous admixture) – from 27.21 ± 3.4 to 7.14 ± 1.23 (p < 0.01) and an increase in the following parameters: reflection index – from 42.2 ± 2.0 to 66.2 ± 4.9% (p < 0.05), virus-specific IgG level – from 134 ± 125 to 669 ± 164 (p < 0. 05), blood flow velocity in arterioles – from 473 ± 108 to 868 ± 64 μm/s (p < 0.05), blood flow velocity in venules – from 299 ± 56 to 862 ± 69 μm/s (p < 0.05), the 6-minute walk distance – from 57.1 ± 4.4 to 328.9 ± 33.7 m (p < 0.05).Conclusion. H2 inhalations were safe and increased the therapeutic effect when added to standard therapy for patients with hypoxemic and hypercapnic RF during exacerbation of COPD in the post-COVID period.
- 11 October 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (5) , 655-667
Open AccessEfficacy and safety of inhaled molecular hydrogen therapy in patients with respiratory failure due to chronic obstructive pulmonary disease exacerbation in post-COVID period
Molecular hydrogen (H2) is a powerful antioxidant and anti-apoptotic agent. H2 has been studied in a number of clinical studies in the recent years.The aim of this research was to investigate the efficacy and safety of H2 inhalation therapy in patients with hypoxemic and hypercapnic respiratory failure (RF) against exacerbation of chronic obstructive pulmonary disease (COPD) in the post-COVID (Corona Virus Disease 2019) period.Methods. The randomized prospective parallel comparative study included patients (n = 60: 40 men aged 71.2 ± 1.8 years, 20 women aged 70.9 ± 2.8 years) with a post-COVID-19 exacerbation of COPD complicated by hypoxemic/hypercapnic RF. The patients were divided into 2 groups: group 1 (main) (n = 30: 18 men, 12 women), group 2 (control) (n = 30: 18 men, 12 women). To maintain arterial blood saturation ≥ 90 %, patients in both groups received respiratory support (non-invasive ventilation) using the Prisma 25ST device (Lowenstein Medical, Germany) in the BiPAP S/T mode (BiLevel Positive Airway Pressure Spontaneous/Time spontaneous/forced mode 20–24/4–6 cm H2O and O2, respectively; the fractional oxygen concentration in the inhaled gas mixture was ≥ 24%). In addition to standard treatment, patients in the main group received additional H2 therapy (Suisonia device, Japan) through a nasal cannula for 90 minutes daily for 14 days.Results. In patients of the main group, a decrease in the stiffness index was detected from 14.6 ± 1.2 to 6.2 ± 0.6 m/s, and the arterial blood lactate level – from 2.84 ± 0.1 to 0.02 ± 0.1 mmol/l (p < 0.001), the calculated shunt fraction Qs/Qt (venous admixture) – from 27.21 ± 3.4 to 7.14 ± 1.23 (p < 0.01) and an increase in the following parameters: reflection index – from 42.2 ± 2.0 to 66.2 ± 4.9% (p < 0.05), virus-specific IgG level – from 134 ± 125 to 669 ± 164 (p < 0. 05), blood flow velocity in arterioles – from 473 ± 108 to 868 ± 64 μm/s (p < 0.05), blood flow velocity in venules – from 299 ± 56 to 862 ± 69 μm/s (p < 0.05), the 6-minute walk distance – from 57.1 ± 4.4 to 328.9 ± 33.7 m (p < 0.05).Conclusion. H2 inhalations were safe and increased the therapeutic effect when added to standard therapy for patients with hypoxemic and hypercapnic RF during exacerbation of COPD in the post-COVID period.
- Open Access
- 10 April 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (3) , 3517
Changes in the proteomics of exhaled breath condensate under the influence of inhaled hydrogen in patients with post-COVID syndrome
Aim. To study the effect of inhalation therapy with an active hydrogen (AH) on the protein composition of exhaled breath condensate (EBC) in patients with post-COVID syndrome (PCS).Material and methods. This randomized controlled parallel prospective study included 60 patients after coronavirus disease 2019 (COVID-19) with PCS during the recovery period and clinical manifestations of chronic fatigue syndrome who received standard therapy according to the protocol for managing patients with chronic fatigue syndrome (CFS). The patients were divided into 2 groups: group 1 (main) — 30 people who received standard therapy and AH inhalations (SUISONIA, Japan) for 10 days, and group 2 (control) — 30 medical workers who received only standard therapy. Patients in both groups were comparable in sex and mean age. All participants in the study were sampled with EBC on days 1 and 10. Samples were subjected to tryptic digestion and high-performance liquid chromatography combined with tandem mass spectrometry analysis using a nanoflow chromatograph (Dionex 3000) in tandem with a high-resolution time-of-flight mass spectrometer (timsTOF Pro).Results. A total of 478 proteins and 1350 peptides were identified using high resolution mass spectrometry. The number of proteins in samples after AH therapy, on average, is 12% more than before treatment. An analysis of the distribution of proteins in different groups of patients showed that only half of these proteins (112) are common for all groups of samples and are detected in EBC before, after, and regardless of hydrogen therapy. In addition to the qualitative difference in the EBC protein compositions in different groups, quantitative changes in the concentration of 36 proteins (mainly structural and protective) were also revealed, which together made it possible to reliably distinguish between subgroups before and after treatment. It is worth noting that among these proteins there are participants of blood coagulation (а-1-antitrypsin), chemokine- and cytokine-mediated inflammation, and a number of signaling pathways (cytoplasmic actin 2), response to oxidative stress (thioredoxin), glycolysis (glyceraldehyde-3- phosphate dehydrogenase), etc.Conclusion. The use of hydrogen therapy can contribute to the switching of a number of physiological processes, which may affect the success of recovery in PCS patients. In particular, the obtained results indicate the activation of aerobic synthesis of adenosine triphosphate in mitochondria by hydrogen therapy, which correlates well with the decrease in the blood lactate level detected by laboratory studies. At the same time, this therapy can inhibit pro-inflammatory activity, negatively affecting the coagulation and signaling pathways of integrins and apoptosis, and, in addition, activate protective pathways, tricarboxylic acid cycle, FAS signaling, and purine metabolism, which may be essential for effective recovery after COVID-19.
- 10 April 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (3) , 3517
Open AccessChanges in the proteomics of exhaled breath condensate under the influence of inhaled hydrogen in patients with post-COVID syndrome
Aim. To study the effect of inhalation therapy with an active hydrogen (AH) on the protein composition of exhaled breath condensate (EBC) in patients with post-COVID syndrome (PCS).Material and methods. This randomized controlled parallel prospective study included 60 patients after coronavirus disease 2019 (COVID-19) with PCS during the recovery period and clinical manifestations of chronic fatigue syndrome who received standard therapy according to the protocol for managing patients with chronic fatigue syndrome (CFS). The patients were divided into 2 groups: group 1 (main) — 30 people who received standard therapy and AH inhalations (SUISONIA, Japan) for 10 days, and group 2 (control) — 30 medical workers who received only standard therapy. Patients in both groups were comparable in sex and mean age. All participants in the study were sampled with EBC on days 1 and 10. Samples were subjected to tryptic digestion and high-performance liquid chromatography combined with tandem mass spectrometry analysis using a nanoflow chromatograph (Dionex 3000) in tandem with a high-resolution time-of-flight mass spectrometer (timsTOF Pro).Results. A total of 478 proteins and 1350 peptides were identified using high resolution mass spectrometry. The number of proteins in samples after AH therapy, on average, is 12% more than before treatment. An analysis of the distribution of proteins in different groups of patients showed that only half of these proteins (112) are common for all groups of samples and are detected in EBC before, after, and regardless of hydrogen therapy. In addition to the qualitative difference in the EBC protein compositions in different groups, quantitative changes in the concentration of 36 proteins (mainly structural and protective) were also revealed, which together made it possible to reliably distinguish between subgroups before and after treatment. It is worth noting that among these proteins there are participants of blood coagulation (а-1-antitrypsin), chemokine- and cytokine-mediated inflammation, and a number of signaling pathways (cytoplasmic actin 2), response to oxidative stress (thioredoxin), glycolysis (glyceraldehyde-3- phosphate dehydrogenase), etc.Conclusion. The use of hydrogen therapy can contribute to the switching of a number of physiological processes, which may affect the success of recovery in PCS patients. In particular, the obtained results indicate the activation of aerobic synthesis of adenosine triphosphate in mitochondria by hydrogen therapy, which correlates well with the decrease in the blood lactate level detected by laboratory studies. At the same time, this therapy can inhibit pro-inflammatory activity, negatively affecting the coagulation and signaling pathways of integrins and apoptosis, and, in addition, activate protective pathways, tricarboxylic acid cycle, FAS signaling, and purine metabolism, which may be essential for effective recovery after COVID-19.
- 30 April 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (2) , 216-225
Effects of inhaled nitric oxide in chronic obstructive pulmonary disease patients with hypercapnic respiratory failure and pulmonary hypertension
Therapy with inhaled nitric oxide (iNO) in patients with hypercapnic respiratory failure (RF) and pulmonary arterial hypertension (PAH) is currently of scientific interest. The aim of this study was to evaluate the effects of iNO therapy on COPD patients with hypercapnic RF and PAH during exacerbation of the disease.Methods. A randomized, prospective, controlled trial included 30 patients with COPD (age 65 (62; 75) years) with hypercapnic RF and pulmonary arterial hypertension (PAH) treated at the State Budgetary City Teaching Hospital “City Clinical Hospital named after D.D.Pletnev of Healthcare Moscow City Department” (2021). The inclusion criteria were: PaCO2 ≥ 45 mm Hg and pulmonary artery systolic pressure PASP > 40 mm Hg as accessed by Doppler echocardiography. The patients were divided into two groups. Patients of the main group were administered iNO in the form of daily 90-minute sessons for two weeks using Tianoks device (Russian Federal Nuclear Center – All-Russian Research Institute of Experimental Physics, State Corporation “Rosatom”, Russia). Patients of the control group received treatment that corresponded to the severity of their COPD exacerbation according to the guidelines by Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020 – 2021. Hemodynamics and gas exchange, exercise tolerance, vascular stiffness, and obstructive disorders were assessed at baseline, on Days 7 and 14.Results. The main group demonstrated a decrease in PASP (38 (32; 43) mm Hg vs 47 (44; 54) mm Hg; p = 0.001), a decrease in stiffness index (SI) (7.03 m / s (5.3; 19.2) vs 12.2 m / s (5.7; 15.1); p = 0.01), decrease the pulmonary shunt fraction (Qs / Qt) (4.33% (3.7; 6.1) vs 9.12% (7.12; 11.3); p = 0.01), an increase in arterial vascular tone measured by reflective index (RI) (62.4% (51.2; 64.3) vs 58.5% (51.7; 63.8); p = 0.01), and increased exercise tolerance measured by 6-minute walking test (6MWT) (358.1 m (320.5; 368.2) vs 321.5 m (280.4; 329.1); p = 0.001) as compared to the control group.Conclusion. Our study indicates that iNO-therapy effectively reduces hypoxemia, endothelial dysfunction, improves hemodynamics, walking distance, and exercise tolerance during the exacerbation of COPD in patients with hypercapnic RF and PAH.
- 30 April 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (2) , 216-225
Effects of inhaled nitric oxide in chronic obstructive pulmonary disease patients with hypercapnic respiratory failure and pulmonary hypertension
Therapy with inhaled nitric oxide (iNO) in patients with hypercapnic respiratory failure (RF) and pulmonary arterial hypertension (PAH) is currently of scientific interest. The aim of this study was to evaluate the effects of iNO therapy on COPD patients with hypercapnic RF and PAH during exacerbation of the disease.Methods. A randomized, prospective, controlled trial included 30 patients with COPD (age 65 (62; 75) years) with hypercapnic RF and pulmonary arterial hypertension (PAH) treated at the State Budgetary City Teaching Hospital “City Clinical Hospital named after D.D.Pletnev of Healthcare Moscow City Department” (2021). The inclusion criteria were: PaCO2 ≥ 45 mm Hg and pulmonary artery systolic pressure PASP > 40 mm Hg as accessed by Doppler echocardiography. The patients were divided into two groups. Patients of the main group were administered iNO in the form of daily 90-minute sessons for two weeks using Tianoks device (Russian Federal Nuclear Center – All-Russian Research Institute of Experimental Physics, State Corporation “Rosatom”, Russia). Patients of the control group received treatment that corresponded to the severity of their COPD exacerbation according to the guidelines by Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020 – 2021. Hemodynamics and gas exchange, exercise tolerance, vascular stiffness, and obstructive disorders were assessed at baseline, on Days 7 and 14.Results. The main group demonstrated a decrease in PASP (38 (32; 43) mm Hg vs 47 (44; 54) mm Hg; p = 0.001), a decrease in stiffness index (SI) (7.03 m / s (5.3; 19.2) vs 12.2 m / s (5.7; 15.1); p = 0.01), decrease the pulmonary shunt fraction (Qs / Qt) (4.33% (3.7; 6.1) vs 9.12% (7.12; 11.3); p = 0.01), an increase in arterial vascular tone measured by reflective index (RI) (62.4% (51.2; 64.3) vs 58.5% (51.7; 63.8); p = 0.01), and increased exercise tolerance measured by 6-minute walking test (6MWT) (358.1 m (320.5; 368.2) vs 321.5 m (280.4; 329.1); p = 0.001) as compared to the control group.Conclusion. Our study indicates that iNO-therapy effectively reduces hypoxemia, endothelial dysfunction, improves hemodynamics, walking distance, and exercise tolerance during the exacerbation of COPD in patients with hypercapnic RF and PAH.
- Open Access
- 15 March 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (3) , 372-377
Hydrogen effect on the mechanisms of mucosal immunity in patients with COVID-19
Aim. To study the inhalation of an active form of hydrogen effect to mucosal and system immunity in a rehabilitation program for health workers. Materials and methods. The study involved patients that survived COVID-19 after therapy with inhaled hydrogen for 90 minutes (n=30), and a control group of patients treated according to standard protocol for managing patients that survived COVID-19 during the rehabilitation period (n=30). Biomaterial was carried out in 2 stages: on the first day of the study, before the accepted therapy and on the 10th day of the study. The indicators of humoral and cellular immunity were studied. The levels of secretory immunoglobulin A (sIgA) and IgG were investigated using the method of enzyme-linked immunosorbent assay. Phagocytosis was assessed on a Beckman Coulter FC-500 flow cytometer. Statistical data processing was carried out in the GraphPad Prism 7.00 software using nonparametric methods. Results. It was shown that the phagocytic index (PI) of monocytes in nasal scrapings after inhaled hydrogen treatment did not significantly change relative to the first day of treatment and control, while the PI of granulocytes in nasal scrapings significantly increased relative to the first day by 2.5 times (p=0.000189), as well as relative to the control by 1.1 times (p=0.047410). PI of monocytes in pharyngeal scrapings showed a significant increase relative to the first day of treatment by 2.8 times (p=0.041103), however, did not differ relative to the control. PI of granulocytes of pharyngeal scraping did not differ significantly relative to the first day and control. PI of granulocytes and blood monocytes of the studied group did not change significantly. PI of granulocytes and monocytes of peripheral blood relative to control during therapy did not change. The sIgA level in nasal scrapings significantly increased by 2.9 times, while in pharyngeal scrapings the level of sIgA significantly decreased by 2 times. Сonclusion. We have shown an increase in granulocytes PI in the nasal cavity and oral monocytes, as well as in the level of sIgA in the nasal cavity during therapy with active hydrogen. The data obtained indicate the effectiveness of therapy, which can be used both in the treatment of COVID-19, and in post-COVID syndrome as an additional therapy. The absence of changes in blood parameters, as well as individual links in nasal and pharyngeal scrapings, requires further study to develop ways to overcome treatment tolerance.
- 15 March 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (3) , 372-377
Open AccessHydrogen effect on the mechanisms of mucosal immunity in patients with COVID-19
Aim. To study the inhalation of an active form of hydrogen effect to mucosal and system immunity in a rehabilitation program for health workers. Materials and methods. The study involved patients that survived COVID-19 after therapy with inhaled hydrogen for 90 minutes (n=30), and a control group of patients treated according to standard protocol for managing patients that survived COVID-19 during the rehabilitation period (n=30). Biomaterial was carried out in 2 stages: on the first day of the study, before the accepted therapy and on the 10th day of the study. The indicators of humoral and cellular immunity were studied. The levels of secretory immunoglobulin A (sIgA) and IgG were investigated using the method of enzyme-linked immunosorbent assay. Phagocytosis was assessed on a Beckman Coulter FC-500 flow cytometer. Statistical data processing was carried out in the GraphPad Prism 7.00 software using nonparametric methods. Results. It was shown that the phagocytic index (PI) of monocytes in nasal scrapings after inhaled hydrogen treatment did not significantly change relative to the first day of treatment and control, while the PI of granulocytes in nasal scrapings significantly increased relative to the first day by 2.5 times (p=0.000189), as well as relative to the control by 1.1 times (p=0.047410). PI of monocytes in pharyngeal scrapings showed a significant increase relative to the first day of treatment by 2.8 times (p=0.041103), however, did not differ relative to the control. PI of granulocytes of pharyngeal scraping did not differ significantly relative to the first day and control. PI of granulocytes and blood monocytes of the studied group did not change significantly. PI of granulocytes and monocytes of peripheral blood relative to control during therapy did not change. The sIgA level in nasal scrapings significantly increased by 2.9 times, while in pharyngeal scrapings the level of sIgA significantly decreased by 2 times. Сonclusion. We have shown an increase in granulocytes PI in the nasal cavity and oral monocytes, as well as in the level of sIgA in the nasal cavity during therapy with active hydrogen. The data obtained indicate the effectiveness of therapy, which can be used both in the treatment of COVID-19, and in post-COVID syndrome as an additional therapy. The absence of changes in blood parameters, as well as individual links in nasal and pharyngeal scrapings, requires further study to develop ways to overcome treatment tolerance.
- Open Access
- 10 March 2021
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 496 (1) , 44-47
Thermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection
The high efficiency of using thermoheliox (inhalation with a high-temperature mixture of helium and oxygen) in the treatment of patients affected by COVID-19 was shown. The dynamics of accumulation of IgG, IgM, and C-reactive protein (CRP) in patients with coronavirus infection in the “working” and control groups was studied experimentally. It was shown that thermoheliox intensifies the synthesis of IgG, IgM, and CRP antibodies, while eliminating the induction period on the kinetic curves of the synthesis of specific antibodies in the IgG form and transfers the synthesis of CRP to a fast phase. The results of experiments confirm the previously obtained data based on the analysis of the kinetic model of the development of coronaviral infection in the human body.
- 10 March 2021
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 496 (1) , 44-47
Open AccessThermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection
The high efficiency of using thermoheliox (inhalation with a high-temperature mixture of helium and oxygen) in the treatment of patients affected by COVID-19 was shown. The dynamics of accumulation of IgG, IgM, and C-reactive protein (CRP) in patients with coronavirus infection in the “working” and control groups was studied experimentally. It was shown that thermoheliox intensifies the synthesis of IgG, IgM, and CRP antibodies, while eliminating the induction period on the kinetic curves of the synthesis of specific antibodies in the IgG form and transfers the synthesis of CRP to a fast phase. The results of experiments confirm the previously obtained data based on the analysis of the kinetic model of the development of coronaviral infection in the human body.